These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 35419860)

  • 1. The kinetics and predictors of anti-SARS-CoV-2 antibodies up to 8 months after symptomatic COVID-19: A Czech cross-sectional study.
    Štěpánek L; Janošíková M; Štěpánek L; Nakládalová M; Boriková A
    J Med Virol; 2022 Aug; 94(8):3731-3738. PubMed ID: 35419860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. COVID-19 symptom duration predicts immunoglobulin G seropositivity.
    Stepanek L; Nakladalova M; Stepanek L; Janosikova M; Borikova A; Vildova H
    Bratisl Lek Listy; 2021; 122(12):861-865. PubMed ID: 34904847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kinetics of SARS-CoV-2 Specific and Neutralizing Antibodies over Seven Months after Symptom Onset in COVID-19 Patients.
    Zhu L; Xu X; Zhu B; Guo X; Xu K; Song C; Fu J; Yu H; Kong X; Peng J; Huang H; Zou X; Ding Y; Bao C; Zhu F; Hu Z; Wu M; Shen H
    Microbiol Spectr; 2021 Oct; 9(2):e0059021. PubMed ID: 34550000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between Acute-Phase Symptoms and Immunoglobulin G Seropositivity up to Eight Months after COVID-19.
    Štěpánek L; Janošíková M; Nakládalová M; Štěpánek L; Tihelka A; Boriková A; Večeřová R; Sauer P
    Medicina (Kaunas); 2022 May; 58(6):. PubMed ID: 35743971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kinetics of specific anti-SARS-CoV-2 IgM, IgA, and IgG responses during the first 12 months after SARS-CoV-2 infection: A prospective longitudinal study.
    Amellal H; Assaid N; Charoute H; Akarid K; Maaroufi A; Ezzikouri S; Sarih M
    PLoS One; 2023; 18(7):e0288557. PubMed ID: 37437051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Difference in SARS-CoV-2 Antibody Status Between Patients With Cancer and Health Care Workers During the COVID-19 Pandemic in Japan.
    Yazaki S; Yoshida T; Kojima Y; Yagishita S; Nakahama H; Okinaka K; Matsushita H; Shiotsuka M; Kobayashi O; Iwata S; Narita Y; Ohba A; Takahashi M; Iwasa S; Kobayashi K; Ohe Y; Yoshida T; Hamada A; Doi T; Yamamoto N
    JAMA Oncol; 2021 Aug; 7(8):1141-1148. PubMed ID: 34047762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Seroprevalence of SARS-CoV-2-specific anti-spike IgM, IgG, and anti-nucleocapsid IgG antibodies during the second wave of the pandemic: A population-based cross-sectional survey across Kashmir, India.
    Lone KS; Khan SMS; Qurieshi MA; Majid S; Pandit MI; Haq I; Ahmad J; Bhat AA; Bashir K; Bilquees S; Fazili AB; Hassan M; Jan Y; Kaul RR; Khan ZA; Mushtaq B; Nazir F; Qureshi UA; Raja MW; Rasool M; Asma A; Bhat AA; Chowdri IN; Ismail S; Jeelani A; Kawoosa MF; Khan MA; Khan MS; Kousar R; Lone AA; Nabi S; Qazi TB; Rather RH; Sabah I; Sumji IA
    Front Public Health; 2022; 10():967447. PubMed ID: 36276377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of S1-, S2-, and NCP-Specific IgM, IgA, and IgG Antibody Kinetics in Acute SARS-CoV-2 Infection by a Microarray and Twelve Other Immunoassays.
    Semmler G; Traugott MT; Graninger M; Hoepler W; Seitz T; Kelani H; Karolyi M; Pawelka E; Aragón de La Cruz S; Puchhammer-Stöckl E; Aberle SW; Stiasny K; Zoufaly A; Aberle JH; Weseslindtner L
    J Clin Microbiol; 2021 Apr; 59(5):. PubMed ID: 33602698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of IgG antibodies against SARS-CoV-2 among healthcare workers in a tertiary pediatric hospital in Poland.
    Kasztelewicz B; Janiszewska K; Burzyńska J; Szydłowska E; Migdał M; Dzierżanowska-Fangrat K
    PLoS One; 2021; 16(4):e0249550. PubMed ID: 33793673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SARS-CoV-2 Incidence, signs and symptoms and main risk factors for COVID-19 infection in Health Care Workers: A hospital-wide survey in Salvador, Brazil.
    Montaño-Castellón I; Lins-Kusterer L; Luz E; Pedroso C; Paz M; Brites C
    Braz J Infect Dis; 2022; 26(4):102387. PubMed ID: 35905929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of Anti-SARS-CoV-2 Specific Antibodies in Health-Care Workers Compared to General Population during an Early Phase of the Pandemic, Tehran-Iran.
    Mortezagholi S; Rostamzadeh D; Alinejad M; Younesi V; Tabarsi P; Shabani M
    Iran J Immunol; 2021 Mar; 18(1):82-92. PubMed ID: 33787517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response and Duration of Serum Anti-SARS-CoV-2 Antibodies After Inactivated Vaccination Within 160 Days.
    Xu QY; Xue JH; Xiao Y; Jia ZJ; Wu MJ; Liu YY; Li WL; Liang XM; Yang TC
    Front Immunol; 2021; 12():786554. PubMed ID: 35003104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SARS-CoV-2 IgG response in symptomatic and asymptomatic COVID-19-infected healthcare workers.
    Cordova E; Bacelar B; Nieto F; Garibaldi F; Aguirre V; Machuca M; Badia M; Rodriguez C
    Occup Med (Lond); 2021 Aug; 71(4-5):215-218. PubMed ID: 34008016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term persistence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein-specific and neutralizing antibodies in recovered COVID-19 patients.
    Chansaenroj J; Yorsaeng R; Puenpa J; Wanlapakorn N; Chirathaworn C; Sudhinaraset N; Sripramote M; Chalongviriyalert P; Jirajariyavej S; Kiatpanabhikul P; Saiyarin J; Soudon C; Thienfaidee O; Ayuthaya TPN; Brukesawan C; Intharasongkroh D; Chaiwanichsiri D; Issarasongkhram M; Kitphati R; Mungaomklang A; Thitithanyanont A; Nagavajara P; Poovorawan Y
    PLoS One; 2022; 17(4):e0267102. PubMed ID: 35446889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Seroprevalence of antibodies to SARS-CoV-2 in healthcare workers & implications of infection control practice in India.
    Gupta R; Dwivedi T; Gajendra S; Sahoo B; Gupta SK; Vikas H; Singh AR; Mohan A; Bhatnagar S; Singh S; Wundavalli L; Guleria R
    Indian J Med Res; 2021 Jan & Feb; 153(1 & 2):207-213. PubMed ID: 33642348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of SARS-CoV-2-specific antibodies via rapid diagnostic immunoassays in COVID-19 patients.
    Chansaenroj J; Yorsaeng R; Posuwan N; Puenpa J; Sudhinaraset N; Chirathaworn C; Poovorawan Y
    Virol J; 2021 Mar; 18(1):52. PubMed ID: 33750394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody responses to SARS-CoV-2 nucleocapsid and spike proteins in hospitalized patients with COVID-19: A multicenter, retrospective, cross-sectional study in Japan.
    Hibino M; Watanabe S; Tobe S; Maeda K; Horiuchi S; Nishiguchi S; Iwase A; Uryu K; Kobayashi S; Kondo T
    Respir Investig; 2022 Mar; 60(2):256-263. PubMed ID: 34924308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kinetics of SARS-CoV-2 IgM and IgG Antibodies 3 Months after COVID-19 Onset in Moroccan Patients.
    Assaid N; Arich S; Charoute H; Akarid K; Anouar Sadat M; Maaroufi A; Ezzikouri S; Sarih M
    Am J Trop Med Hyg; 2023 Jan; 108(1):145-154. PubMed ID: 36509045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SARS-CoV-2 Seroprevalence Among Health Care Workers in Major Private and Public Hospitals With COVID-19 Patient's Referral in Tehran, Iran.
    Darvishian M; Sharafkhah M; Mohammadi Z; Sadeghniiat-Haghighi K; Abdollahi A; Jafary M; Talaschian M; Tabarsi P; Baghai P; Mardani M; Shayanrad A; Shafighian F; Markarian M; Roozafzai F; Zamani M; Alvand S; Hariri S; Sadeghi A; Poustchi H; Malekzadeh R
    Front Public Health; 2022; 10():832003. PubMed ID: 35400056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differing kinetics of anti-spike protein IgGs and neutralizing antibodies against SARS-CoV-2 after Comirnaty (BNT162b2) immunization.
    Bonura F; De Grazia S; Bonura C; Sanfilippo GL; Giammanco GM; Amodio E; Ferraro D
    J Appl Microbiol; 2022 May; 132(5):3987-3994. PubMed ID: 35083832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.